Table 2 Univariate and multivariate analysis of clinical, histological and molecular variables associated with time to recurrence

From: SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis

Variable

Univariate

HR (95% CI), P

Multivariate

HR (95% CI), P

Age

0.99 (0.96–1.03), 0.7167

 

Female gender

1.24 (0.62–2.75), 0.5525

 

Relevant comorbiditiesa

0.90 (0.48–1.64), 0.7370

 

HCV positive

1.19 (0.56–2.12), 0.5550

 

HBV positive

0.97 (0.42–1.97), 0.9279

 

History of alcohol abuse

0.91 (0.49–1.65), 0.7676

 

Clinically relevant portal hypertension

1.63 (0.89–2.96), 0.1131

 

Child–Pugh B

2.12 (1.01–4.13), 0.0479

1.62 (0.71–3.37), 0.2387

MELD

0.99 (0.85–1.15), 0.9905

 

BCLC B-Ca

1.87 (1.01–3.46), 0.0472

1.61 (0.85–3.02), 0.1434

High SERPINB3 mRNA

2.10 (1.10–3.86), 0.0268

2.30 (1.14–4.46), 0.0214

High TGF-β1 mRNA

1.03 (0.86–1.21), 0.7731

 

High β-catenin mRNA

1.18 (0.89–1.23), 0.8815

 

Alpha fetoprotein (log 10 μg l−1)

1.16 (0.88–1.49), 0.2772

 

Macroscopic vascular invasion

0.97 (0.39–3.24), 0.9563

 

Microscopic vascular invasion

1.59, (0.88–2.89), 0.1218

 

Poorly differentiated grade

1.14 (0.61–2.08), 0.6767

 

Operative time

1.00 (0.99–1.01), 0.5319

 

Blood loss

1.00 (0.99–1.00), 0.3822

 
  1. Abbreviations: BCLC=Barcelona Clinic Liver Cancer; CI=confidence interval; CRPH=clinically relevant portal hypertension; HBV=hepatitis B virus; HCV=hepatitis C virus; HR=hazard ratio; MELD=model end-stage liver disease score. The values in bold are statistically significant (P<0.05).
  2. aBCLC classification according to imaging results.
Back to article page